Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Gains from Sales and Divestitures (2022 - 2025)

Protagonist Therapeutics' Gains from Sales and Divestitures history spans 7 years, with the latest figure at $380000.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 19.97% year-over-year to $380000.0; the TTM value through Dec 2025 reached $380000.0, up 19.97%, while the annual FY2025 figure was $380000.0, 19.97% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $380000.0 at Protagonist Therapeutics, up from $75500.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $380000.0 in Q4 2025 and bottomed at $75500.0 in Q3 2025.
  • The 5-year median for Gains from Sales and Divestitures is $104712.0 (2022), against an average of $150923.0.
  • The largest annual shift saw Gains from Sales and Divestitures tumbled 40.4% in 2021 before it surged 177.85% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $78165.0 in 2021, then soared by 38.76% to $108462.0 in 2022, then grew by 5.11% to $114000.0 in 2023, then soared by 177.85% to $316748.0 in 2024, then rose by 19.97% to $380000.0 in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Gains from Sales and Divestitures are $380000.0 (Q4 2025), $75500.0 (Q3 2025), and $316748.0 (Q4 2024).